Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
News|Slideshows|March 31, 2022
American College of Cardiology 71st Scientific Sessions: Science Preview, April 2, 2022
Author(s)Patient Care Editorial Staff
ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.
Advertisement
At the American College of Cardiology's 71st Scientific Session in Washington, DC, April 2-4, the latest findings spanning the breadth of cardiovascular disease research will be presented in late-breaking science sessions on all 3 days.
Whether you are attending in person or remotely, use these quick slide-show guides to review sessions and study titles. Use the "late-breaking" link to visit the ACC program page where all study abstracts will be available as the findings are presented. Start below with the hot topics on Day 1, including research on mavacamten, sotagliflozin , and bentracimab.
Advertisement
Related to this article
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement